Future perspectives in the treatment of atopic dermatitis

Journal of Dermatology

Volumn 36, Issue 7, 2009, Pages 367-376

  Katoh, Norito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Barrier; Biologics; Immune regulation; Itchy; Proactive treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPRURITIC AGENT; CALCINEURIN INHIBITOR; CLOPIDOGREL; CYCLOSPORIN A; EFALIZUMAB; EMOLLIENT AGENT; EPICERAM; FLUTICASONE PROPIONATE; GLUCOCORTICOID; HOUSE DUST ALLERGEN; HYDROCORTISONE BUTYRATE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MEVALONIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OMALIZUMAB; PETROLATUM; PIMECROLIMUS; SEMAPHORIN 3A; TACROLIMUS; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; BASOPHIL; BURNING SENSATION; DENDRITIC CELL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; EPIDERMIS; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE; MAST CELL; NONHUMAN; PATHOGENESIS; RECOMMENDED DRUG DOSE; REVIEW; SKIN ATROPHY; SYSTEMIC THERAPY; THROMBOCYTE;

ADMINISTRATION, TOPICAL; ANTIPRURITICS; CALCINEURIN; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; EPIDERMIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 67651214069     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2009.00662.x     Document Type: Review

References (84)

1. Bieber T. Atopic dermatitis. N Engl J Med 2008 358 : 1483 1494.
2. Leung DYM, Boguniewicz M, Howell MD et al. New insights into atopic dermatitis. J Clin Invest 2004 113 : 651 657. (Pubitemid 38544154)
3. Cork MJ, Robinson DA, Vasilopoulos Y et al. New perspective on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. J Allergy Clin Immunol 2006 118 : 3 21. (Pubitemid 43946484)
4. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006 38 : 441 446.
5. Hoffjan S, Epplen JT. The genetics of atopic dermatitis: recent findings and future options. J Mol Med 2005 83 : 682 692. (Pubitemid 41225110)
6. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol 2006 154 : 719 725. (Pubitemid 43374098)
7. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006 118 : 152 169. (Pubitemid 43946480)
8. Furue M, Saeki H, Furukawa F et al. Guidelines for management of atopic dermatitis. (Abstract). Jpn J Dermatol 2008 118 : 325 342.
9. Katoh N, Hirano S, Kishimoto S. Prognostic factor of adult patients with atopic dermatitis. J Dermatol 2008 35 : 477 483.
10. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008 121 : 1337 1343.
11. Nemoto-Hasebe I, Akiyama M, Nomura T, Sandilands A, McLean WH, Shimizu H. Clinical severity correlates with impaired barrier in filaggrin-related eczema. J Invest Dermatol 2009 129 : 682 689.
12. Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest 1992 90 : 482 487.
13. Katoh N, Hirano S, Kishimoto S, Yasuno H. Acute cutaneous barrier perturbation induces maturation of Langerhans' cells in hairless mice. Acta Derm Venereol 1997 77 : 365 369. (Pubitemid 27376594)
14. Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol 1998 28 : 769 779. (Pubitemid 28116188)
15. Wakamori T, Katoh N, Hirano S, Kishimoto S, Ozasa K. Atopic dermatitis, dry skin and serum IgE in children in a community in Japan. Int Arch Allergy Immunol 2009 149 : 103 110.
16. Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003 4 : 771 788. (Pubitemid 37452637)
17. Cork MJ, Britton J, Butler L, Young S, Murphy R, Keohane SG. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003 149 : 582 589. (Pubitemid 37281592)
18. Haratake A, Ikenaga K, Katoh N, Uchiwa H, Hirano S, Yasuno H. Topical mevalonic acid stimulates de novo cholesterol synthesis and epidermal permeability barrier homeostasis in aged mice. J Invest Dermatol 2000 114 : 247 252. (Pubitemid 30417757)
19. Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol 2000 143 : 524 531. (Pubitemid 30743337)
20. Sugarman JL, Parish LJ. A topical physiologic lipid-based, barrier repair formulation (Epiceram cream) is highly effective monotherapy for moderate-to-severe pediatric atopic dermatitis: a multicenter, investigator-blinded trial comparing a barrier repair formulation, Epiceram, to fluticasone proprionate (Cutivate) cream (Abstract). J Invest Dermatol 2008 128 (Suppl S54.
21. Cookson W. The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004 4 : 978 988. (Pubitemid 39620072)
22. Vasilopoulos Y, Cork MJ, Murphy R et al. Genetic association between an AACC insertion in the 3′UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol 2004 123 : 62 66. (Pubitemid 38833464)
23. Kato A, Fukai K, Oiso N, Hosomi N, Murakami T, Ishii M. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol 2003 148 : 665 669. (Pubitemid 36629743)
24. Nin M, Katoh N, Kokura S, Handa O, Yoshikawa T, Kishimoto S. Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes. J Dermatol Sci 2009 54 : 17 24.
25. Anigbogu AN, Maibach HI. Topical corticosteroid therapy. In : Millikan LE, ed. Drug Therapy in Dermatology. New York : Marcel Decker, Inc 2000 1 29.
26. Löwenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2008 73 : 1025 1029.
27. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005 211 : 174 187. (Pubitemid 41160263)
28. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005 330 : 516.
29. Luger T, Van Leent EJ, Graeber M et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001 144 : 788 794. (Pubitemid 32374782)
30. Abramovits W, Fleischer AB Jr., Jaracz E, Breneman D. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. J Drugs Dermatol 2008 7 : 1153 1158.
31. Katoh N, Hirano S, Yasuno H, Kishimoto S. Effects of tacrolimus ointment on facial eruption, itch, and scratching in patients with atopic dermatitis. J Dermatol 2004 31 : 194 199. (Pubitemid 38478348)
32. Inoue T, Katoh N, Kishimoto S. Prolonged topical application of tacrolimus inhibits immediate hypersensitivity reactions by reducing degranulation of mast cells. Acta Derm Venereol 2006 86 : 13 16. (Pubitemid 46939781)
33. Senba E, Katanosaka K, Yajima H, Mizumura K. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res 2004 50 : 257 262. (Pubitemid 39370892)
34. Munzenberger PJ, Montejo JM. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy 2007 27 : 1020 1028. (Pubitemid 46986689)
35. Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007 127 : 808 816. (Pubitemid 46434650)
36. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep 2006 6 : 270 274. (Pubitemid 44056822)
37. Fonacier L, Charlesworth EN, Spergel JM et al. The black box warning for topical calcineurin inhibitors: looking outside the box. Ann Allergy Asthma Immunol 2006 97 : 117 120. (Pubitemid 44156349)
38. Mihm MC Jr., Soter NA, Dvorak HF, Austen KF. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976 67 : 305 312.
39. Peserico A, Städtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008 158 : 801 807.
40. Wollenberg A, Reitamo S, Girolomoni G et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008 63 : 742 750.
41. Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003 326 : 1367.
42. Kronke M, Leonard WJ, Depper JM et al. Cyclosporin A inhibits T cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1984 81 : 5214 5218. (Pubitemid 14011293)
43. Schmitt J, Schmitt N, Meurer M. Cyclosporine in the treatment of patients with atopic eczema - systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007 21 : 606 619. (Pubitemid 46916758)
44. van Joost T, Kozel MM, Tank B, Troost R, Prens EP. Cyclosporine in atopic dermatitis. Modulation in the expression of immunologic markers in lesional skin. J Am Acad Dermatol 1992 27 : 922 928.
45. Wahlgren CF. Itch and atopic dermatitis. clinical and experimental studies. Acta Derm Venereol 1991 165 (Suppl 1 53.
46. Belloni B, Andres C, Ollert M, Ring J, Mempel M. Novel immunological approaches in the treatment of atopic eczema. Curr Opin Allergy Clin Immunol 2008 8 : 423 427.
47. Bußmann C, Bieber T, Novak N. Systemic therapeutic options for severe atopic dermatitis. J Dtsch Dermatol Ges 2009 7 : 205 219.
48. Katoh N, Hirano S, Suehiro M, Masuda K, Kishimoto S. The characteristics of patients with atopic dermatitis demonstrating a positive reaction in a scratch test after 48 hours against house dust mite antigen. J Dermatol 2004 31 : 720 726. (Pubitemid 39410188)
49. Katoh N, Kraft S, Wessendorf JH, Bieber T. The high-affinity IgE receptor (FcεRI) blocks apoptosis in normal human monocytes. J Clin Invest 2000 105 : 183 190. (Pubitemid 30054357)
50. Asai K, Kitaura J, Kawakami Y et al. Regulation of mast cell survival by IgE. Immunity 2001 14 : 791 800. (Pubitemid 32592425)
51. Watanabe M, Satoh T, Yamamoto Y, Kanai Y, Karasuyama H, Yokozeki H. Overproduction of IgE induces macrophage-derived chemokine (CCL22) secretion from basophils. J Immunol 2008 181 : 5653 5659.
52. Holgate ST, Djukananovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases. An update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005 35 : 408 416. (Pubitemid 40577231)
53. Belloni B, Ziai M, Lim A et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007 120 : 1223 1225. (Pubitemid 350047479)
54. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006 54 : 68 72. (Pubitemid 41832460)
55. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005 53 : 338 340. (Pubitemid 40979597)
56. Schmid-Grendelmeier P, Flückiger S, Disch R et al. IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol 2005 115 : 1068 1075. (Pubitemid 40616225)
57. Altrichter S, Kriehuber E, Moser J, Valenta R, Kopp T, Stingl G. Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol 2008 128 : 2232 2239.
58. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001 164 : S1 S5.
59. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunothreapy. J Allergy Clin Immunol 2003 112 : 915 922. (Pubitemid 37412059)
60. Werfel T, Breuer K, Ruéff F et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006 61 : 202 205. (Pubitemid 43381831)
61. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G et al. Classical and alternative macrophage activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion. Immunobiology 2006 211 : 487 501. (Pubitemid 44241651)
62. Xystrakis E, Urry Z, Hawrylowicz CM. Regulatory T cell therapy as individualized medicine for asthma and allergy. Curr Opin Allergy Clin Immunol 2007 7 : 535 541. (Pubitemid 350076450)
63. Fujita S, Yamashita N, Ishii Y et al. Regulatory dendritic cells protect against allergic airway inflammation in a murine asthmatic model. J Allergy Clin Immunol 2008 121 : 95 104.
64. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol Mech Dis 2008 3 : 279 312.
65. Caproni M, Torchia D, Antiga E, Volpi W, del Bianco E, Fabbri P. The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis. J Clin Immunol 2006 26 : 370 375. (Pubitemid 44051384)
66. Greaves MW. Recent advances in pathophysiology and current management of itch. Ann Acad Med Singapore 2007 36 : 788 792. (Pubitemid 350219088)
67. Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci 2006 7 : 535 547. (Pubitemid 43995431)
68. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999 5 : 1522 1525.
69. Dillon SR, Sprecher C, Hammond A et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004 5 : 752 760. (Pubitemid 39023308)
70. Bilsborough J, Leung DY, Maurer M et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 2006 117 : 418 425. (Pubitemid 43190155)
71. Grimstad O, Sawanobori Y, Vestergaard C et al. Anti-interleukin-31- antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 2009 18 : 35 43.
72. Tominaga M, Ozawa S, Tengara S, Ogawa H, Takamori K. Intraepidermal nerve fibers increase in dry skin of acetone-treated mice. J Dermatol Sci 2007 48 : 103 111. (Pubitemid 47381570)
73. Yamaguchi J, Nakamura F, Aihara M et al. Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model. J Invest Dermatol 2008 128 : 2842 2849.
74. Mukai K, Matsuoka K, Taya C et al. Basophils play a critical role in the development of IgE-mediated chronic allergic inflammation independently of T cells and mast cells. Immunity 2005 23 : 191 202. (Pubitemid 41169288)
75. Obata K, Mukai K, Tsujimura Y et al. Basophils are essential initiators of a novel type of chronic allergic inflammation. Blood 2007 110 : 913 920. (Pubitemid 47267429)
76. Karasuyama H, Mukai K, Tsujimura Y, Obata K. Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol 2009 9 : 9 13.
77. Gober MD, Gaspari AA. Allergic contact dermatitis. Curr Dir Autoimmun 2008 10 : 1 26.
78. Soumelis V, Reche PA, Kanzler H et al. Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nat Immunol 2002 3 : 673 680. (Pubitemid 34752477)
79. Allakhverdi Z, Comeau MR, Jessup HK et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007 204 : 253 258. (Pubitemid 46294541)
80. Katoh N. Platelet as versatile regulators of cutaneous inflammation. J Dermatol Sci 2009 53 : 89 95.
81. Soga F, Katoh N, Inoue T, Kishimoto S. Serotonin activates human monocytes and prevents apoptosis. J Invest Dermatol 2007 127 : 1947 1955. (Pubitemid 47075377)
82. Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Platelet-derived microparticles and soluble P-selectin as platelet activation markers in patients with atopic dermatitis. Clin Immunol 2009 131 : 495 500.
83. Tamagawa-Mineoka R, Katoh N, Ueda E, Takenaka H, Kita M, Kishimoto S. The role of platelets in leukocyte recruitment in chronic contact hypersensitivity induced by repeated elicitation. Am J Pathol 2007 170 : 2019 2029. (Pubitemid 47339275)
84. Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelets play important roles in the late phase of the immediate hypersensitivity reaction. J Allergy Clin Immunol 2009 123 : 581 587, 587. e1 9.